HR
PRTK

Howe & Rusling’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Howe & Rusling’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-275
Closed -$1K – 905
2019
Q4 		$1K Buy
+275
New +$954 ﹤0.01% 808

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Howe & Rusling's PRTK Position: Q1 2020 in Review

Howe & Rusling sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2020, closing a stake of 275 shares — an estimated $1K sold.

Howe & Rusling first reported a position in PRTK in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 85 funds tracked by Wall St. Rank hold PRTK as of Q1 2020.

  • Howe & Rusling reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Howe & Rusling sold 275 Paratek Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1K.
  • Howe & Rusling first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Howe & Rusling's Paratek Pharmaceuticals, Inc. position peaked at $1K in Q4 2019.
  • 85 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.